INVEST IN BETA BIONICS – Building a bionic pancreas to improve the lives of people with type 1 diabetes

INVEST IN BETA BIONICS

Building a bionic pancreas to improve the lives of people with type 1 diabetes

At Beta Bionics, Inc., we have developed a bionic pancreas called the iLet™, a pocket-sized, wearable medical device that autonomously manages blood sugar levels in people with diabetes. Our iLet technology has demonstrated dramatic improvements in clinical outcomes. Through its ability to continuously adapt to the ever-changing insulin needs of people with diabetes, the iLet is the quintessential embodiment of personalized medicine – a sturdy and irrevocable bridge to the ever-elusive cure.

Square_cropped_large_cropped_damiano

Edward Damiano
CEO, BETA BIONICS
 
 
 

OUR AMBITION

We are driven to build a technology that will automatically manage our children’s diabetes, day and night, and keep them safe from the far-reaching harms, the immediate dangers, the emotional burden, and the fear that type 1 diabetes carries with it every day of their lives. That technology will provide a bridge that spans the divide between where we are today and the biological cure of tomorrow – a cure that has been ever present in our dreams, and ever elusive from our lives.

KEY FACTS

  • 6 outpatient human clinical trials already completed.
  • Backed by nearly 10 years of clinical data.

 

Summary:
We are driven to build a technology that will automatically manage our children’s diabetes, day and night, and keep them safe from the far-reaching harms, the immediate dangers, the emotional burden, and the fear that type 1 diabetes carries with it every day of their lives.

Youtube: https://youtu.be/bZXmfTxd79Q
See Campaign: http://wefunder.com/beta.bionics
Contact Information:
Edward Damiano

Tags:
wefunder, English, Crowdfunding, United States, Equity

image

The post INVEST IN BETA BIONICS – Building a bionic pancreas to improve the lives of people with type 1 diabetes appeared first on iCrowdNewswire.

Source: ICNW

Compartir Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn





Related News

Comments are Closed